mRNA flu shots move into trials.

@article{Dolgin2021mRNAFS,
  title={mRNA flu shots move into trials.},
  author={Elie S. Dolgin},
  journal={Nature reviews. Drug discovery},
  year={2021}
}
  • E. Dolgin
  • Published 11 October 2021
  • Medicine
  • Nature reviews. Drug discovery
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
TLDR
The three-dose regimen strategy of the mRNA-RBD vaccine proposed in the present study appears to be a promising reference for the development of mRNA vaccines targeting SARS-CoV-2 variants.
Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response
TLDR
This review highlights the current progress and advances in the development of RIVs in the context of heterosubtypic immunity induction toward universal vaccine production, and discussed existing knowledge on influenza and vaccine development, current hemagglutinin-based RIV's in the market and in the pipeline, other potential vaccine targets for RIVS, and deantigenization process.
Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
TLDR
The current state of this problem is covered and future directions for RNA-based flu vaccine development are suggested to suggest future directions.
Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies
TLDR
A perspective on the purpose, value, and challenges associated with potency testing for vaccines produced by new technologies is provided in the light of experience gained with recombinant protein-based vaccines, which offer the opportunity to directly correlate in vitro antigenicity with in vivo immunogenicity.
Global Pandemic Preparedness: Optimizing Our Capabilities and the Influenza Experience
TLDR
The coronavirus disease 2019 (COVID-19) pandemic has prompted rapid investigation and deployment of vaccine platforms never before used to combat human disease, and existing well-established, proven platforms for seasonal and pandemic influenza manufacturing will also continue to be utilized to rapidly address the next influenza threat.
Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination
TLDR
A perspective on the potential short- and long-term evolutionary dynamics of seasonal influenza is offered and potential consequences and mitigation strategies as global travel gradually returns to pre-pandemic levels are discussed.
Opportunities and challenges for commercializing microarray patches for vaccination from a MAP developer’s perspective
TLDR
Significant advances in microarray patch (MAP) technology are starting to make needle-free delivery of a broad range of vaccines an achievable goal, but key challenges remain in the commercialization of MAP technology and its adoption, including market acceptance, scale-up of production, regulatory approval, and the availability of capital to build advanced manufacturing infrastructure.
...
...